## Mitchell Levine

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6707057/publications.pdf

Version: 2024-02-01

394286 302012 1,571 44 19 citations h-index papers

g-index 45 45 45 2450 docs citations times ranked citing authors all docs

39

#	Article	IF	CITATIONS
1	Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs. PLoS ONE, 2022, 17, e0266663.	1.1	8
2	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. European Journal of Health Economics, 2021, 22, 723-733.	1.4	7
3	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e707-e714.	2.2	40
4	Health programmes and services addressing the prevention and management of infectious diseases in persons who inject drugs in Canada: a systematic integrative review protocol. BMJ Open, 2020, 10, e035188.	0.8	4
5	Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines. Journal of Population Therapeutics and Clinical Pharmacology, 2020, 27, e1-e24.	1.9	1
6	An Exploratory Analysis of Predictors of Concordance Between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta. Healthcare Policy, 2020, 15, 90-101.	0.3	2
7	Evaluation of online clinical pharmacology curriculum resources for medical students. British Journal of Clinical Pharmacology, 2019, 85, 2599-2604.	1.1	5
8	Frailty and Risk of Fractures in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 507-513.	4.3	75
9	A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers. PharmacoEconomics - Open, 2019, 3, 437-451.	0.9	6
10	Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis. Clinical and Investigative Medicine, 2019, 42, E53-E65.	0.3	27
11	Prescribing competency assessment for Canadian medical students: a pilot evaluation. Canadian Medical Education Journal, 2019, 10, e103-e110.	0.3	2
12	A Systematic Survey of Control Groups in Behavioral and Social Science Trials. Research on Social Work Practice, 2018, 28, 538-545.	1.1	5
13	PP51 Updating Canadian Pharmaceutical Budget Impact Analysis Guidelines. International Journal of Technology Assessment in Health Care, 2018, 34, 86-86.	0.2	1
14	Enhancing research publications and advancing scientific writing in health research collaborations: sharing lessons learnt from the trenches. Journal of Multidisciplinary Healthcare, 2018, Volume 11, 245-254.	1.1	6
15	A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 821-854.	0.7	15
16	Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? & mp; ndash; A systematic review of reviews: an update. Journal of Multidisciplinary Healthcare, 2018, Volume 11, 495-510.	1.1	69
17	Exploring the characteristics, global distribution and reasons for retraction of published articles involving human research participants: a literature survey. Journal of Multidisciplinary Healthcare, 2018, Volume 11, 39-47.	1.1	28
18	In older adults with COPD, new opioid use was linked to increased risk for respiratory and all-cause mortality. Annals of Internal Medicine, 2017, 166, JC11.	2.0	1

#	Article	IF	Citations
19	Reduction in targeted potentially inappropriate medication use in elderly inpatients: a pragmatic randomized controlled trial. European Journal of Clinical Pharmacology, 2017, 73, 1237-1245.	0.8	33
20	Aspirin plus clopidogrel was not linked to risk for cancer compared with aspirin alone or no antiplatelets. Annals of Internal Medicine, 2017, 167, JC10.	2.0	1
21	Knowledge Translation Strategy to Reduce the Use of Potentially Inappropriate Medications in Hospitalized Elderly Adults. Journal of the American Geriatrics Society, 2016, 64, 2487-2494.	1.3	17
22	Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting. International Journal of Cardiology, 2016, 203, 893-899.	0.8	2
23	Patient-specific academic detailing for smoking cessation: feasibility study. Canadian Family Physician, 2014, 60, e16-23.	0.1	4
24	Evidence against the Involvement of Chronic Cerebrospinal Venous Abnormalities in Multiple Sclerosis. A Case-Control Study. PLoS ONE, 2013, 8, e72495.	1.1	20
25	The process of medication management for older adults with dementia. Journal of Nursing and Healthcare of Chronic Illness, 2011, 3, 407-418.	0.5	31
26	Correction to the Relative Risk Calculation for Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis. Radiology, 2010, 255, 307-308.	3.6	4
27	Goal attainment for multiple cardiovascular risk factors in communityâ€based clinical practice (a) Tj ETQq1 1 0.	784314 rg 0.9	BT <mark>/</mark> Overlock
28	Clinical and Economic Effects of a Therapeutic Substitution Policy for Proton Pump Inhibitors in Aboriginal Patients in Northern Communities in Canada???s Northwest Territories. Disease Management and Health Outcomes, 2008, 16, 175-182.	0.3	2
29	Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. Annals of Internal Medicine, 2008, 148, 379.	2.0	655
30	GPs' approach to insulin prescribing in older patients: a qualitative study. British Journal of General Practice, 2008, 58, 569-575.	0.7	20
31	Do patients' expectations influence their use of medications? Qualitative study. Canadian Family Physician, 2008, 54, 384-93.	0.1	32
32	Sex differences in hospital admissions from emergency departments in asthmatic adults: a population-based study. Annals of Allergy, Asthma and Immunology, 2006, 96, 666-672.	0.5	44
33	A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. Journal of Evaluation in Clinical Practice, 2006, 12, 463-470.	0.9	21
34	Community-based evaluation of etanercept in patients with rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 665-70.	1.0	14
35	Effect of Gender, Age, and Severity of Asthma Attack on Patterns of Emergency Department Visits due to Asthma by Month and Day of the Week. European Journal of Epidemiology, 2005, 20, 947-956.	2.5	13
36	Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?. BMC Endocrine Disorders, 2005, 5, 1.	0.9	40

#	Article	IF	CITATIONS
37	A Study of Patient Responses to a Perceived Change in Salbutamol Metered Dose Inhalers. Journal of Generic Medicines, 2005, 2, 201-208.	0.0	3
38	The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I-Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2004, 20, 31-40.	0.8	38
39	The 2004 Canadian recommendations for the management of hypertension: Part IITherapy. Canadian Journal of Cardiology, 2004, 20, 41-54.	0.8	70
40	Valuing Knowledge and the Knowledge of Values: Understanding Guideline-Incongruent Prescribing. Journal of Clinical Pharmacology, 2002, 42, 475-476.	1.0	6
41	The 2001 Canadian recommendations for the management of hypertension: Part two-Therapy. Canadian Journal of Cardiology, 2002, 18, 625-41.	0.8	44
42	An Algorithm to Aid in the Investigation of Thalassemia Trait in Multicultural Populations. Archives of Pathology and Laboratory Medicine, 2000, 124, 1320-1323.	1.2	10
43	The Evaluation of Various Mathematical RBC Indices and Their Efficacy in Discriminating Between Thalassemic and Non-Thalassemic Microcytosis. American Journal of Clinical Pathology, 1996, 106, 201-205.	0.4	74
44	Saliva Versus Blood Sampling for Therapeutic Drug Monitoring in Children. Therapeutic Drug Monitoring, 1994, 16, 437-443.	1.0	63